Pfizer completes acquisition of Ferrosan Consumer Health’s Business
1 December 2011 | By Pfizer
Pfizer Inc. have announced that it has completed its previously announced acquisition of Ferrosan Consumer Health’s business...
List view / Grid view
News
Roche’s cobas EGFR Mutation Test for personalized treatment of non-small cell lung cancer receives CE mark
1 December 2011 | By Roche
Roche have announced that the cobas EGFR Mutation Test is now CE marked...
Abbott receives FDA clearance for new test to detect Vitamin D levels
Abbott announced today it has received clearance from the U.S. Food and Drug Administration for a fully-automated 25-OH Vitamin D assay performed on its widely used ARCHITECT® laboratory testing platform.
Teva announces agreement with Ranbaxy regarding Generic Lipitor®
30 November 2011 | By Teva
A portion of the profits from Ranbaxy’s sales of Atorvastatin Calcium Tablets during Ranbaxy’s 180-day first-to-file exclusivity period, will be paid to Teva...
Roche to present important new data for HER2-positive breast cancer at 2011 SABCS
30 November 2011 | By Roche
Results from studies to be presented at SABCS...
FDA accepts ELIQUIS® (apixaban) New Drug Application for review
29 November 2011 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. FDA has accepted for review a NDA for ELIQUIS® (apixaban)...
Sanofi confirms its decades-long commitment to the fight against Malaria
29 November 2011 | By Sanofi
Sanofi organizes the 10th Edition of the Pan-African Conference against Malaria with representatives of 34 African Countries...
KOMBOGLYZE™ receives marketing authorisation in the European Union for adult patients with Type 2 diabetes
29 November 2011 | By AstraZeneca
The European Commission has granted marketing authorisation for KOMBOGLYZE™...
ONGLYZA® (saxagliptin) approved for use in Europe as combination therapy with insulin in adults with type 2 diabetes
28 November 2011 | By Bristol-Myers Squibb Company
The European Commission has approved ONGLYZA® (saxagliptin)...
AstraZeneca commits an additional $100 million to venture capital arm MedImmune Ventures
28 November 2011 | By AstraZeneca
MedImmune Ventures closes investment in Australian company, NeuProtect Pty Ltd...
EDURANT® (rilpivirine) approved in Europe
28 November 2011 | By Daniel J Edelman Ltd
The European Commission has granted marketing authorisation for EDURANT® (rilpivirine)...
Cambridge-Elan Centre for Research Innovation and Drug Discovery launched
28 November 2011 | By F T I Consulting
World’s leading researchers work together on therapeutic advances in neuroscience...
Novartis gains European Commission approval for Rasitrio®
28 November 2011 | By Novartis
Rasitrio®, the first triple combination of aliskiren, amlodipine and hydrochlorothiazide in a single pill has received approval...
Abbott expands agreement with GSK to include development of a companion diagnostic test for an additional investigational cancer immunotherapy antigen
28 November 2011 | By Abbott
Abbott announced that it will expand its existing agreement with GSK...
Gilead receives European marketing authorization for Eviplera®
28 November 2011 | By Gilead Sciences Inc
Gilead Sciences, Inc. announced that the European Commission has granted marketing authorization for Eviplera®...
